Levodropropizine

Summary

Levodropropizine (CHEMBL1288810) is a phase-3 clinical-stage small-molecule antitussive (ATC R05DB27); indicated across 3 conditions including bronchial disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: R05DB27
• Indications: 3 conditions
• Clinical trials: 6
• Chemistry: 236.31 Da · C13H20N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1288810
Name	Levodropropizine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	65859
ChEBI	CHEBI:82722
ATC	R05DB27
Molecular formula	C13H20N2O2
Molecular weight	236.31
InChIKey	PTVWPYVOOKLBCG-ZDUSSCGKSA-N

SMILES: C1CN(CCN1C[C@@H](CO)O)C2=CC=CC=C2

IUPAC name: (2S)-3-(4-phenylpiperazin-1-yl)propane-1,2-diol

ChEBI definition: A member of the class of N-arylpiperazines that is N-phenylpiperazine in which the amino hydrogen is replaced by a 2,3-dihydroxypropyl group (the S-enantiomer). A peripherally acting antitussive drug that is used as an alternative to opioids.

Pharmacological roles (ChEBI): antitussive.

Also known as: (-)-dropropizine, (s)-(-)-dropropizine, Danka, Dipropizine, (s)-isomer, Dropropizine s-form, Dropropizine, (s)-, L-dropropizine, Levodropropizina, Levodropropizine, Levopront, Levotuss, Rapitux

Patent coverage: 512 distinct patent families (1,341 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADRA2B	5.02	AC50	9600	nM	CHEMBL_ACT_25144069

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bronchial disorder	3	MONDO:0001358	EFO:1002018

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE3	3
PHASE4	1
PHASE2/PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06907355	PHASE4	COMPLETED	CHAO Tos: Codeina, HederA Helix, LevOdropropizina Para la TOS
NCT01177852	PHASE3	WITHDRAWN	Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2-12 Years Old,Suffering From Cough and Acute Rhinitis
NCT01416480	PHASE3	COMPLETED	Clinical Trial to Evaluate the Safety and Efficacy of Theobromine Capsule as an Antitussive in Acute Cougher
NCT03489837	PHASE3	COMPLETED	Phase III Study to Evaluate the Efficacy and Safety of HOB-048 CR Tab. in Comparison With HOB-048 Syrup in Patients With Cough Due to Acute or Chronic Bronchitis
NCT06252454	PHASE2/PHASE3	UNKNOWN	The Impact of Inhaled Furosemide and Perorally Administered Levodropropizine on Dyspnea in Patients With Respiratory Diseases
NCT01573663	PHASE1	COMPLETED	A Drug-Drug Interaction Study of Ambroxol and Levodropropizine

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).